Пути улучшения качества жизни больных немелкоклеточным раком легкого с метастазами в головной мозг

The analysis of the results of combined usage of temodal and radiotherapy among 37 patients with non-small-cell lung cancer (NSCLC) IIIA, IIIB stages with brain metastases was held. The comparative analysis of two groups was held: the 1 st group 27 patients with NSCLC, administered radiotherapy according to the above mentioned scheme with lomustine chemo modification, 40 mg per week (TFD 120-160 mg); the 2 nd group 30 patients with NSCLC, administered radiotherapy according to the same scheme without any modification. During the process of therapy one could observe improvement of neurological state of majority of patients in main group and control groups 1 and 2 (85.3%, 86.9%, 88.8%), respectively. Total survival rate of patients in main group was 16%, and median was 8 months, while in the 1 st group this parameter was 5.5%, median was 6.2 months, respectively, Рnd group no patient survived one-year term and median was 4 months. Following the treatment one could admit that combined usage of temodal and radiotherapy improves direct results, median and one-year survival rate among the patients of this category, saving the quality of their life according to the analysis data of hematological and non-hematological reactions.